Utility of cell-free DNA from bronchial washing fluid in diagnosis and genomic determination for radiology-suspected pulmonary nodules
Zhang, Xinyu,Yu, Zhuo,Xu, Yaping,Chao, Yencheng,Hu, Qin,Li, Chun,Ye, Maosong,Zhu, Xiuli,Cui, Liang,Bai, Jing,Gong, Yuhua,Guan, Yanfang,Zhou, Min,Huang, Jian’an,Zhang, Hua,Ren, Tao,Shen, Qian,Wang, Kai,Hou, Yingyong,Xia, Xuefeng,Pu, Xingxiang,Carbone, David P.,Zhang, Xin
DOI: https://doi.org/10.1038/s41416-022-01969-2
IF: 9.075
2022-01-01
British Journal of Cancer
Abstract:Bronchial washing fluid (BWF) is a less-invasive specimen. Due to the limited sensitivity of BWF cellular component diagnosis, the aim of this study was to explore the potential role of BWF supernatant as a source of liquid biopsy of lung cancer. This prospective study enrolled 76 suspected and 5 progressed lung cancer patients. Transbronchial biopsy tissues, BWF supernatant (BWF_Sup) and BWF precipitant (BWF_Pre) were tested by a targeted panel of 1021 genes. BWF_Sup cell-free DNA (cfDNA) was superior to tissue biopsy and BWF_Pre in determining mutational allele frequency, tumour mutational burden, and chromosomal instability. Moreover, BWF_Sup and BWF_Pre achieved comparable efficacy to tissue samples in differentiating malignant and benign patients, but only BWF_Sup persisted differentiated performance after excluding 55 malignancies pathologically diagnosed by bronchoscopic biopsy. Among 67 malignant patients, 82.1% and 71.6% of tumour-derived mutations (TDMs) were detected in BWF_Sup and BWF_Pre, respectively, and the detectability of TDMs in BWF_Sup was independent of the cytological examination of BWF. BWF_Sup outperformed BWF_Pre in providing more subclonal information and thus might yield advantage in tracking drug-resistant markers. BWF_Sup cfDNA is a reliable medium for lung cancer diagnosis and genomic profiles and may provide important information for subsequent therapeutic regimens.